From Evidence to Practice: Denosumab in  Osteoporosis and Joint Health

Dr SANJAY AGARWALA; Dr DHANANJAY GUPTA; Dr SANJAY YADAV; Dr VIJAY GONI; Dr ANIL MEHTANI; Dr KAMAL BACHANI; Dr  SUBHASH JANGID; Dr SUDHIR SETH; Dr NIRAD VEGSARKAR; Dr SHUBHRANSHU SHEKHAR MOHANTY; Dr PRADEEP BHOSALE; Dr HEMANT BHANDARI

doi:10.59793/ijcp.v35i1.1042

Authors

Dr SANJAY AGARWALA Dr Sanjay Agarwala Head-Orthopedics and Traumatology; Director-Professional Services, PD Hinduja Hospital & Medical Research Centre, Mumbai, Maharashtra, India
Dr DHANANJAY GUPTA Director and Senior Consultant, Orthopedics and Joint Reconstruction and Replacement Surgeon, Fortis Flt Lt Rajan Dhall Hospital, Vasant Kunj, New Delhi, India
Dr SANJAY YADAV HOD, Dept. of Orthopedics, Aruna Asaf Ali Government Hospital, New Delhi, India
Dr VIJAY GONI Professor, Dept. of Orthopedic Surgery, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Punjab, India
Dr ANIL MEHTANI Director, Pediatric (Ped) Orthopedics, Max Smart Super Speciality Hospital, Saket, New Delhi; Max Hospital, Gurugram, Haryana; India
Dr KAMAL BACHANI Director of Orthopedics and Chief Ortho Surgeons, AO Specialty Centre, Malviya Nagar, New Delhi, India
Dr SUBHASH JANGID Director and HOD, Bone and Joint Institute Speciality: Robotic and Computer Navigated Joint Reconstruction, Fortis Memorial Research Institute, Gurugram, Haryana, India
Dr SUDHIR SETH Consultant Orthopedic Surgeon and Director at Ortho Point, Chittaranjan Park, New Delhi, India; Associated with Fortis C-DOC, Apollo Spectra, Max Healthcare, National Heart Institute and Rockland Hospital
Dr NIRAD VEGSARKAR Consultant, Orthopedic Surgeon, Lilavati Hospital, Mumbai, Maharashtra, India
Dr SHUBHRANSHU SHEKHAR MOHANTY Consultant Orthopedics and Joint Replacement Surgeon, Jaslok, Shushrusha and Nanavati Hospitals, Mumbai, Maharashtra, India
Dr PRADEEP BHOSALE Senior Director-Robotic Joint Replacement Surgery, Hip and Knee; Nanavati Max Super Speciality Hospital, Mumbai, Maharashtra, India
Dr HEMANT BHANDARI Joint Replacement, Arthroscopy, Trauma and Orthopedic Surgeon, Bombay Hospital and Medical Research Center, Maharashtra, India

DOI:

https://doi.org/10.59793/ijcp.v35i1.1042

Keywords:

Osteoporosis,, osteopenia,, fracture,, denosumab,, joint replacement therapy, avascular necrosis

Abstract

Osteoporosis and osteopenia are prevalent conditions in India, particularly among postmenopausal women and the elderly,
leading to increased fracture risks and morbidity. Denosumab, a monoclonal antibody, demonstrates superior efficacy
over other treatments in reducing fracture risk and enhancing bone mineral density (BMD). Clinical trials highlight its
effectiveness in preventing periprosthetic bone loss, improving implant stability, and mitigating femoral head collapse in
various conditions; combination therapies involving denosumab further amplify BMD gains and reduce fracture risk. The
article reviews the efficacy and safety of denosumab in managing osteoporosis, joint replacement therapy, and avascular
necrosis based on a review of clinical evidence and studies. Denosumab emerges as a cornerstone therapy for osteoporosis
management, offering multifaceted benefits in fracture prevention, joint replacement therapy, and avascular necrosis.